Sort
10,766 grants matching “checkpoint inhibitor”
Resistance mechanisms to autophagy-modulating therapies
$669,910Ravi K Amaravadi · University Of Pennsylvania · R01 · FY2022 · CA
Atherosclerosis, Prostaglandin Inhibition and Checkpoint Blockade
$669,855Garret A Fitzgerald · University Of Pennsylvania · R01 · FY2021 · HL
Imaging Acidosis and Immune Therapy in PDAC
$669,832Shari Pilon-Thomas · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2022 · CA
Imaging Acidosis and Immune Therapy in PDAC
$669,832Shari Pilon-Thomas · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2023 · CA
Exploiting the VISTA Pathway to Prevent Acute GVHD and Control Steroid Refractory Disease
$669,698Bruce R. Blazar · University Of Minnesota · R01 · FY2023 · HL
Variation in tumor-associated immune profiles and colorectal cancer outcomes
$669,492Stephanie L. Schmit · Cleveland Clinic Lerner Com-Cwru · R01 · FY2022 · CA
Data Processing, Analysis and Modeling Unit
$669,457Jeremy Goecks · Oregon Health & Science University · U2C · FY2022 · CA
A precision oncology approach to integrating of tumor microenvironment suppressive cell modulators to enhance antitumor immunity
$669,436Dung T Le · Johns Hopkins University · P01 · FY2021 · CA
A precision oncology approach to integrating of tumor microenvironment suppressive cell modulators to enhance antitumor immunity
$669,436Dung T Le · Johns Hopkins University · P01 · FY2025 · CA
Structure and function of RAD51 paralog tumor suppressor complexes in genome maintenance
$669,325Shaun Olsen · University Of Texas Hlth Science Center · R01 · FY2024 · CA
Synthetic lethalities to cell cycle disruption in glioma
$668,921Rameen Beroukhim · Dana-Farber Cancer Inst · R01 · FY2022 · CA
Multiplexed drug testing of micro-dissected tumors using a microfluidic platform with integrated electrochemical aptasensors
$668,910Albert Folch · University Of Washington · R01 · FY2023 · CA
Transfer Application - R01 CA223804 - Chemoimmunoprevention of EGFR-Driven Non-Small Cell Lung Cancer
$668,650Ming You · Methodist Hospital Research Institute · R01 · FY2022 · CA
Targeting natural killer cells to enhance HIV vaccine responses
$668,632Stephen N. Waggoner · Cincinnati Childrens Hosp Med Ctr · R01 · FY2020 · AI
Therapeutic Targeting of NSD2 in Lung Adenocarcinoma
$668,588Pawel K. Mazur · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA
Targeting the CD73-adenosinergic pathway in head and neck cancer
$668,298Yan Cui · Augusta University · R01 · FY2024 · DE
Leveraging fructose transport to create a privileged substrate to selectively fuel T cells
$668,212Kayvan R Keshari · Sloan-Kettering Inst Can Research · R01 · FY2024 · CA
Immunotherapy of Uveal Melanoma using PRAME Vaccine in Combination with Adoptive T Cell Therapy
$668,196Cassian Yee · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA
New Approaches to Modeling and Targeting Cyclin E-amplified High-Grade Serous Tubo-Ovarian Carcinoma
$668,154Benjamin G. Neel · New York University School Of Medicine · R01 · FY2024 · CA
Assessment of germline variants associated with immune-related adverse events following immune checkpoint inhibitors
$668,053Toni Choueiri · Dana-Farber Cancer Inst · R01 · FY2025 · CA
Modulating the PD-1/PD-L1 checkpoint to promote antitumor activity of HER2 CAR T cells in patients with sarcoma
$667,761Meenakshi G Hegde · Baylor College Of Medicine · R01 · FY2023 · CA
Impact of Interventions on Clonally Expanded Proviruses and Their RNA Expression
$667,617Mary Kearney · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
Metabolic regulation of immunosuppressive myeloid cells in the tumor microenvironment of pancreatic cancer.
$667,601Yaqing Zhang · University Of Michigan At Ann Arbor · R01 · FY2025 · CA
Selective disruption of histone deacetylase complexes using protein interaction modulators
$667,246Marc Vidal · Dana-Farber Cancer Inst · R01 · FY2023 · CA
Response and resistance to SHP2 inhibitors alone and in combination in Non-Small Cell Lung Cancer
$666,956Benjamin G. Neel · New York University School Of Medicine · R01 · FY2024 · CA